Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
The primary goal is to investigate the efficacy of intralymphatic immunotherapy (ILIT) for
the treatment of allergic rhinitis and allergic asthma due to sensitisation to grass pollen
allergens. 60 patients with allergic rhinitis will be included and randomized to receive
either Polvac (n=30) or placebo (n=30). All patients will receive three injections with 4-8
weeks interval. The injections into a inguinal lymph node is guided by sonography.
Patients will record symptoms and medication use in the summer of 2022 and 2023.